The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
about
The mTOR signalling pathway in human cancerTherapeutic Implications of Targeting AKT Signaling in MelanomaA proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosisIdentification of glycogen synthase kinase 3α as a therapeutic target in melanomaThe soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cellsMolecular pathogenesis of sporadic melanoma and melanoma-initiating cells.Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathwayAkt1 deletion prevents lung tumorigenesis by mutant K-ras.The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN CircuitThe complexes of mammalian target of rapamycin.Intrinsic differences between oral and skin keratinocytesComparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.Merlin is a negative regulator of human melanoma growthNon-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanomaDriver mutations in melanoma: lessons learned from bench-to-bedside studiesPTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionDeficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension.Targeting multiple key signaling pathways in melanoma using leelamine.Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathwaysMacrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma.Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma.Targeting sphingosine kinase-1 to inhibit melanoma.Systematic investigation into the role of intermittent high glucose in pancreatic beta-cells.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).Melanoma prevention using topical PBISeVemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cellsPI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanomaAn unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma.Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development.Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.Synthesis and SAR studies of dual AKT/NF-κB inhibitors against melanoma.NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.
P2860
Q24627306-F3DE7299-8F39-4A5E-A5ED-03BA8711181AQ24631438-91E51472-C1A9-46CA-9FE1-9229060E7D4AQ28383207-3E171B90-A784-428E-9603-8DC515C6AF78Q33569998-CAE9F309-99D7-495E-B340-A6099454702DQ33648931-744B4127-4156-4E36-AE0E-B195FB5524A6Q33725172-EF8FB626-DA31-4050-8F68-C7CA249AB596Q33878064-22D446DE-2C5E-437B-9747-E6D793A6F65AQ34049042-DB084657-ABA8-499C-9CC3-4287B9FA339AQ34106285-A88AB88B-07C1-4416-9692-4DE37CB403A9Q34116818-B81AA4A8-A37D-4886-B320-E52D4BF111DCQ34149597-7684B4BD-62B4-444B-B6DF-8AFBFEA6C88EQ34220097-EC3C43AA-BEA4-4C78-850B-4E66C5E88AF0Q34225871-D6014D73-560F-4AAF-B971-FC344A975F84Q34389516-551FDE8F-B6E9-430B-8120-DEB08393C949Q34450728-348D94FC-90EA-4BDD-8AE1-82BDF932BE98Q34639532-B6A9BD19-2E52-44F5-820A-5C7ADA0DB5F0Q34761941-66338B78-06AD-4923-9BB4-22D3FE864E1EQ35115837-2D1DB2A2-DC67-434E-B8A4-76FEE43532A8Q35136450-740C86D8-E0CD-4D83-A11F-FE69218B62BDQ35172795-0A0C02EA-DC42-4C0D-99F5-EF6A79E8E2DDQ35234272-8E3FE177-924B-4113-8F00-E018A20509D3Q35320304-1923AEE0-A0DD-42E3-B112-4FA8766C3822Q35324807-93E167C5-CE99-4504-AEF4-05F85F71E498Q35640196-1F6BB857-4498-4A8C-A8CB-EF296DBA5059Q35789935-8253F422-EF1C-49BB-BE02-53EC8A45F607Q35791508-C98354DB-1EF6-48AF-8F50-A9A5833A67D9Q35911227-1FC923E3-787F-431B-BB9C-76E3BA358101Q36194074-B49F35D2-57F9-4ED0-8C99-5D8EF3B3E96DQ36347314-83235B85-02A6-424C-8C39-AA9CDCFEE47FQ36384802-BF07C2C5-44C5-49A5-BFA7-CDFBABD47C67Q36643680-ECC7F4A6-FBAC-4D9B-9FE8-01754774FE9BQ36652026-8008E5B1-C9E5-4F70-85F6-6D513FB07B23Q36677236-C206C492-7DF0-45C9-B728-D90867CCDDD2Q36689098-2BFE7019-90C9-4584-A32D-7A7E0A154646Q36741115-E9395B1E-6E74-44BB-96BB-4D1EAB4B7338Q36973754-97163FFB-08A7-411E-9050-C49ACDC03EB9Q37231972-704E2720-1C43-47EB-BF95-C6AE01992F06Q37664921-CEE4EA27-6659-4AFD-8BF1-C6CB62FD0C57Q37689575-926A3471-B88F-4182-BD1B-2A85C0E728F9Q37705251-2B2F140F-B333-4997-8B62-8829AC563AF5
P2860
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
@en
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
@nl
type
label
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
@en
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
@nl
prefLabel
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
@en
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
@nl
P2860
P1476
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
@en
P2093
Gavin P Robertson
Subbarao V Madhunapantula
P2860
P304
P356
10.1111/J.1755-148X.2009.00585.X
P577
2009-05-28T00:00:00Z